Year: 2012
Type: editorial
Abstract: It has been a tough challenge to hunt for effective therapeutic targets for acute leukemia bearing mixed lineage leukemia (MLL) fusion genes. The MLL gene which maps to human chromosome 11 band q23 (11q23) is frequently involved in chromosome translocations in around 10 % of total leukemia, including 5-10 % of patients with acute myeloid leukemia (AML) and 80% of infant acute leukemia. The critical feature of MLL-rearrangements is the generation of a chimeric transcript consisting of 5 ’ MLL and 3 ’ sequences of the partner gene; at present, more than 100 different loci which translocate to the MLL gene have been identified and more than 60 different partner genes have been cloned [1]. MLL-rearranged leukemia is usually associated with intermediate to poor prognosis and refractory to
Source: Oncotarget
Authors: Xi Jiang, Jianjun Chen
Institution: University of Chicago
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2159552287